Oxidative stress-induced signaling pathways implicated in the pathogenesis of Parkinson's disease

NeuroMolecular Medicine

Volumn 16, Issue 2, 2014, Pages 217-230

  Gaki, Georgia S ^a   Papavassiliou, Athanasios G ^b  

^a HELLENIC PASTEUR INSTITUTE   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

1 Methyl 4 phenyl 1 2,3,6 tetrahydropyridine (MPTP); Astaxanthin; Oxidative stress; Parkinson's disease; PTEN induced kinase 1 (PINK1); Signaling pathways

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA TOCOPHEROL; ASTAXANTHIN; ENVIRONMENTAL CHEMICAL; MITOCHONDRIAL DNA; PARKIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; PTEN INDUCED KINASE 1; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; TOXIN; UNCLASSIFIED DRUG; ABELSON KINASE; DROSOPHILA PROTEIN; GLUTAMATE RECEPTOR; HEAVY METAL; METALLOPROTEINASE; MITOCHONDRIAL PROTEIN; NEUROPROTECTIVE AGENT; NEUROTOXIN; PARL PROTEIN, HUMAN; PROTEIN KINASE; PTEN-INDUCED PUTATIVE KINASE; UBIQUITIN PROTEIN LIGASE; XANTHOPHYLL;

AMINO TERMINAL SEQUENCE; ARTICLE; BRAIN REGION; CARBOXY TERMINAL SEQUENCE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; ENDOPLASMIC RETICULUM STRESS; ENVIRONMENTAL FACTOR; EXCITOTOXICITY; HUMAN; INFLAMMATION; MICROGLIA; MITOPHAGY; NEUROMODULATION; NEUROPATHOLOGY; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; ANIMAL; APOPTOSIS; BASAL GANGLION; BIOLOGICAL MODEL; CALCIUM SIGNALING; DROSOPHILA MELANOGASTER; DRUG EFFECTS; GENETICS; METABOLISM; MITOCHONDRION; PARKINSONISM; PATHOLOGY; PHYSIOLOGY; TOXICITY;

ANIMALS; APOPTOSIS; BASAL GANGLIA; CALCIUM SIGNALING; DOPAMINERGIC NEURONS; DROSOPHILA MELANOGASTER; DROSOPHILA PROTEINS; HUMANS; METALLOPROTEASES; METALS, HEAVY; MICROGLIA; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; MODELS, NEUROLOGICAL; NEUROPROTECTIVE AGENTS; NEUROTOXINS; OXIDATIVE STRESS; PARKINSON DISEASE; PARKINSONIAN DISORDERS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-ABL; RECEPTORS, GLUTAMATE; SIGNAL TRANSDUCTION; UBIQUITIN-PROTEIN LIGASES; XANTHOPHYLLS;

EID: 84901321275     PISSN: 15351084     EISSN: 15591174     Source Type: Journal    
DOI: 10.1007/s12017-014-8294-x     Document Type: Article

References (138)

1. Akundi, R. S., et al. (2011). Increased mitochondrial calcium sensitivity and abnormal expression of innate immunity genes precede dopaminergic defects in Pink1-deficient mice. PLoS ONE, 6(1), e16038.
2. Alam, Z. I., et al. (1997). Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. Journal of Neurochemistry, 69(3), 1196-1203.
3. Alnemri, E. S. (2007). HtrA2 and Parkinson's disease: Think PINK? Nature Cell Biology, 9(11), 1227-1229.
4. Andersen, J. K. (2004). Oxidative stress in neurodegeneration: Cause or consequence? Nature Medicine, 10(Suppl), S18-S25.
5. Arduino, D. M., Esteves, A. R., & Cardoso, S. M. (2013). Mitochondria drive autophagy pathology via microtubule disassembly: A new hypothesis for Parkinson disease. Autophagy, 9(1), 112-114.
6. Barnham, K. J., Masters, C. L., & Bush, A. I. (2004). Neurodegenerative diseases and oxidative stress. Nature Reviews Drug Discovery, 3(3), 205-214.
7. Beal, M. F. (2003). Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Annals of the New York Academy of Sciences, 991, 120-131.
8. Blum, D., et al. (2001). Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: Contribution to the apoptotic theory in Parkinson's disease. Progress in Neurobiology, 65(2), 135-172.
9. Braak, H., & Braak, E. (2000). Pathoanatomy of Parkinson's disease. Journal of Neurology, 247(Suppl 2), II3-II10.
10. Bueler, H. (2009). Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease. Experimental Neurology, 218(2), 235-246.
11. Busse, W. W., & Lemanske, R. F., Jr. (2001). Asthma. New England Journal of Medicine, 344(5), 350-362.
12. Camps, M., et al. (2005). Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nature Medicine, 11(9), 936-943.
13. Cao, C., et al. (2001). The ARG tyrosine kinase interacts with Siva-1 in the apoptotic response to oxidative stress. Journal of Biological Chemistry, 276(15), 11465-11468.
14. Chan, K. C., Mong, M. C., & Yin, M. C. (2009). Antioxidative and anti-inflammatory neuroprotective effects of astaxanthin and canthaxanthin in nerve growth factor differentiated PC12 cells. Journal of Food Science, 74(7), H225-H231.
15. Ciccone, S., et al. (2013). Parkinson's disease: A complex interplay of mitochondrial DNA alterations and oxidative stress. International Journal of Molecular Sciences, 14(2), 2388-2409.
16. Cilenti, L., et al. (2004). Regulation of HAX-1 anti-apoptotic protein by Omi/HtrA2 protease during cell death. Journal of Biological Chemistry, 279(48), 50295-50301.
17. Clausen, T., et al. (2011). HTRA proteases: Regulated proteolysis in protein quality control. Nature Reviews Molecular Cell Biology, 12, 152-162.
18. Constance, J., Despres, S., Nishida, A., & Lim, C. (2012). Selective targeting of c-Abl via a cryptic mitochondrial targeting signal activated by cellular redox status in leukemic and breast cancer cells. Pharmaceutical Research, 29(8), 2317-2328.
19. Cookson, M. R., & Bandmann, O. (2010). Parkinson's disease: Insights from pathways. Human Molecular Genetics, 19(R1), R21-R27.
20. Corti, O., Lesage, S., & Brice, A. (2011). What genetics tells us about the causes and mechanisms of Parkinson's disease. Physiological Reviews, 91(4), 1161-1218.
21. Costa, A. C., Loh, S. H. Y., & Martins, M. (2013). Drosophila Trap1 protects against mitochondrial dysfunction in a PINK1/parkin model of Parkinson's disease. Cell Death Disease, 4, e467; doi: 10.1038/cddis.2012.205.
22. Crabtree, D. M., & Zhang, J. (2012). Genetically engineered mouse models of Parkinson's disease. Brain Research Bulletin, 88(1), 13-32.
23. Crosiers, D., et al. (2011). Parkinson disease: Insights in clinical, genetic and pathological features of monogenic disease subtypes. Journal of Chemical Neuroanatomy, 42(2), 131-141.
24. Cui, K., et al. (2004). Role of oxidative stress in neurodegeneration: Recent developments in assay methods for oxidative stress and nutraceutical antioxidants. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 28(5), 771-799.
25. Dalle-Donne, I., et al. (2003). Protein carbonylation in human diseases. Trends in Molecular Medicine, 9(4), 169-176.
26. Dawson, T. M., Ko, H. S., & Dawson, V. L. (2010). Genetic animal models of Parkinson's disease. Neuron, 66(5), 646-661.
27. Deas, E., Plun-Favreau, H., & Wood, N. W. (2009). PINK1 function in health and disease. EMBO Mol Med, 1(3), 152-165.
28. Deas, E., et al. (2011). PINK1 cleavage at position A103 by the mitochondrial protease PARL. Human Molecular Genetics, 20(5), 867-879.
29. Esposito, E., et al. (2002). A review of specific dietary antioxidants and the effects on biochemical mechanisms related to neurodegenerative processes. Neurobiology of Aging, 23(5), 719-735.
30. Feng, L. R., & Maguire-Zeiss, K. A. (2010). Gene therapy in Parkinson's disease: Rationale and current status. CNS Drugs, 24(3), 177-192.
31. Fujiwara, H., et al. (2002). Alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nature Cell Biology, 4(2), 160-164.
32. Gao, H. M., et al. (2008). Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. Journal of Neuroscience, 28(30), 7687-7698.
33. Gilgun-Sherki, Y., Melamed, E., & Offen, D. (2001). Oxidative stress induced-neurodegenerative diseases: The need for antioxidants that penetrate the blood brain barrier. Neuropharmacology, 40(8), 959-975.
34. Gollamudi, S., et al. (2012). Concordant signaling pathways produced by pesticide exposure in mice correspond to pathways identified in human Parkinson's disease. PLoS ONE, 7(5), e36191.
35. Gonfloni, S., et al. (2012). Oxidative stress, DNA damage, and c-Abl signaling: At the crossroad in neurodegenerative diseases? International Journal of Cell Biology, 2012, 683097.
36. Graybiel, A. M. (2005). The basal ganglia: Learning new tricks and loving it. Current Opinion in Neurobiology, 15(6), 638-644.
37. Greene, A. W., et al. (2012). Mitochondrial processing peptidase regulates PINK1 processing, import and Parkin recruitment. EMBO Reports, 13(4), 378-385.
38. Gu, G. J., et al. (2013). Elevated MARK2-dependent phosphorylation of Tau in Alzheimer's disease. Journal of Alzheimer's Disease, 33(3), 699-713.
39. Guzman, J. N., et al. (2010). Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature, 468(7324), 696-700.
40. Hald, A., & Lotharius, J. (2005). Oxidative stress and inflammation in Parkinson's disease: Is there a causal link? Experimental Neurology, 193(2), 279-290.
41. Harish, G., et al. (2010). Bioconjugates of curcumin display improved protection against glutathione depletion mediated oxidative stress in a dopaminergic neuronal cell line: Implications for Parkinson's disease. Bioorganic & Medicinal Chemistry, 18(7), 2631-2638.
42. Heeman, B., et al. (2011). Depletion of PINK1 affects mitochondrial metabolism, calcium homeostasis and energy maintenance. Journal of Cell Science, 24(Pt 7), 1115-1125.
43. Henchcliffe, C., & Beal, M. F. (2008). Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nature Clinical Practice Neurology, 4(11), 600-609.
44. Hirsch, E. C., & Hunot, S. (2009). Neuroinflammation in Parkinson's disease: A target for neuroprotection? Lancet Neurology, 8(4), 382-397.
45. Horowitz, M. P., & Greenamyre, J. T. (2010). Gene-environment interactions in Parkinson's disease: The importance of animal modeling. Clinical Pharmacology and Therapeutics, 88(4), 467-474.
46. Ilic, T., et al. (1998). Oxidative stress and Parkinson's disease. Vojnosanitetski Pregled., 55(5), 463-468.
47. Imam, S. Z., et al. (2011). Novel regulation of parkin function through c-Abl-mediated tyrosine phosphorylation: Implications for Parkinson's disease. Journal of Neuroscience, 31(1), 157-163.
48. Inestrosa, N. C., & Arenas, E. (2010). Emerging roles of Wnts in the adult nervous system. Nature Reviews Neuroscience, 11(2), 77-86.
49. Jenner, P. (2003). Oxidative stress in Parkinson's disease. Annals of Neurology, 53(Suppl 3), S26-S36.
50. Jeong, H. K., et al. (2010). Inflammatory responses are not sufficient to cause delayed neuronal death in ATP-induced acute brain injury. PLoS ONE, 10, e13756.
51. Ji, K. A., et al. (2007). Resident microglia die and infiltrated neutrophils and monocytes become major inflammatory cells in lipopolysaccharide-injected brain. Glia, 55(15), 1577-1588.
52. Johnson, K. A., Conn, P. J., & Niswender, C. M. (2009). Glutamate receptors as therapeutic targets for Parkinson's disease. CNS & Neurological Disorders: Drug Targets, 8(6), 475-491.
53. Jones, J. M., et al. (2003). Loss of Omi mitochondrial protease activity causes the neuromuscular disorder of mnd2 mutant mice. Nature, 425(6959), 721-727.
54. Kanthasamy, A. G., et al. (2003). Proteolytic activation of proapoptotic kinase PKCdelta is regulated by overexpression of Bcl-2: Implications for oxidative stress and environmental factors in Parkinson's disease. Annals of the New York Academy of Sciences, 1010, 683-686.
55. Kim, H. et al. (2011). Downregulation of Wnt/beta-catenin signaling causes degeneration of hippocampal neurons in vivo. Neurobiology of Aging, 32(12), 2316 e1-e15.
56. Kim, J., et al. (2013). PINK1 deficiency enhances inflammatory cytokine release from acutely prepared brain slices. Experimental Neurobiology, 22(1), 38-44.
57. Ko, H. S., et al. (2010). Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function. Proceedings of National Academic Science USA, 107(38), 16691-16696.
58. Kumar, K. R., Djarmati-Westenberger, A., & Grunewald, A. (2011). Genetics of Parkinson's disease. Seminars in Neurology, 31(5), 433-440.
59. Kurkowska-Jastrzebska, I., et al. (2004). Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease. International Immunopharmacology, 4(10-11), 1307-1318.
60. Kuwabara, T., et al. (2009). Wnt-mediated activation of NeuroD1 and retro-elements during adult neurogenesis. Nature Neuroscience, 12(9), 1097-1105.
61. Kuzuhara, S., et al. (1988). Lewy bodies are ubiquitinated. A light and electron microscopic immunocytochemical study. Acta Neuropathologica, 75(4), 345-353.
62. L'Episcopo, F., et al. (2010). Glia as a turning point in the therapeutic strategy of Parkinson's disease. CNS & Neurological Disorders: Drug Targets, 9(3), 349-372.
63. L'Episcopo, F., et al. (2011a). Reactive astrocytes and Wnt/beta-catenin signaling link nigrostriatal injury to repair in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine model of Parkinson's disease. Neurobiology of Diseases, 41(2), 508-527.
64. L'Episcopo, F., et al. (2011b). A Wnt1 regulated Frizzled-1/beta-Catenin signaling pathway as a candidate regulatory circuit controlling mesencephalic dopaminergic neuron-astrocyte crosstalk: Therapeutical relevance for neuron survival and neuroprotection. Molecular Neurodegeneration, 6, 49.
65. L'Episcopo, F., et al. (2012). Plasticity of subventricular zone neuroprogenitors in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model of Parkinson's disease involves cross talk between inflammatory and Wnt/beta-catenin signaling pathways: Functional consequences for neuroprotection and repair. Journal of Neuroscience, 32(6), 2062-2085.
66. Langston, J. W., et al. (1984). 1-Methyl-4-phenylpyridinium ion (MPP +): Identification of a metabolite of MPTP, a toxin selective to the substantia nigra. Neuroscience Letters, 48(1), 87-92.
67. Lesage, S., & Brice, A. (2012). Role of Mendelian genes in "sporadic" Parkinson's disease. Parkinsonism & Related Disorders, 18(Suppl 1), S66-S70.
68. Li, W., et al. (2002). Structural insights into the pro-apoptotic function of mitochondrial serine protease HtrA2/Omi. Natural Structural Biology, 9(6), 436-441.
69. Li, B., et al. (2010a). Omi/HtrA2 is a positive regulator of autophagy that facilitates the degradation of mutant proteins involved in neurodegenerative diseases. Cell Death and Differentiation, 17, 1773-1784.
70. Li, X., et al. (2010b). Tetrahydroxystilbene glucoside attenuates MPP + -induced apoptosis in PC12 cells by inhibiting ROS generation and modulating JNK activation. Neuroscience Letters, 483(1), 1-5.
71. Liu, X., et al. (2009). Astaxanthin inhibits reactive oxygen species-mediated cellular toxicity in dopaminergic SH-SY5Y cells via mitochondria-targeted protective mechanism. Brain Research, 1254, 18-27.
72. Logan, C. Y., & Nusse, R. (2004). The Wnt signaling pathway in development and disease. Annual Review of Cell and Developmental Biology, 20, 781-810.
73. Lotharius, J., & Brundin, P. (2002). Pathogenesis of Parkinson's disease: Dopamine, vesicles and alpha-synuclein. Nature Reviews Neuroscience, 3(12), 932-942.
74. Lu, W., et al. (2007). The phosphorylation of tyrosine 332 is necessary for the caspase 3-dependent cleavage of PKCdelta and the regulation of cell apoptosis. Cellular Signalling, 19(10), 2165-2173.
75. Marchetti, B., & Abbracchio, M. P. (2005). To be or not to be (inflamed) - is that the question in anti-inflammatory drug therapy of neurodegenerative disorders? Trends in Pharmacological Sciences, 26(10), 517-525.
76. Marongiu, R., et al. (2009). Mutant Pink1 induces mitochondrial dysfunction in a neuronal cell model of Parkinson's disease by disturbing calcium flux. Journal of Neurochemistry, 108(6), 1561-1574.
77. Martins, L. M., et al. (2004). Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice. Molecular and Cellular Biology, 24(22), 9848-9862.
78. Matenia, D., et al. (2012). Microtubule affinity-regulating kinase 2 (MARK2) turns on phosphatase and tensin homolog (PTEN)-induced kinase 1 (PINK1) at Thr-313, a mutation site in Parkinson disease: Effects on mitochondrial transport. Journal of Biological Chemistry, 287(11), 8174-8186.
79. Matsuda, S., Kitagishi, Y., & Kobayashi, M. (2013). Function and characteristics of PINK1 in mitochondria. Oxidative Medicine and Cellular Longevity, 2013, 601587.
80. Medina, E. A., Morris, I. R., & Berton, M. T. (2010). Phosphatidylinositol 3-kinase activation attenuates the TLR2-mediated macrophage proinflammatory cytokine response to Francisella tularensis live vaccine strain. The Journal of Immunology, 185(12), 7562-7572.
81. Meissner, C., et al. (2011). The mitochondrial intramembrane protease PARL cleaves human Pink1 to regulate Pink1 trafficking. Journal of Neurochemistry, 117(5), 856-867.
82. Min, K. J., et al. (2012). Spatial and temporal correlation in progressive degeneration of neurons and astrocytes in contusion-induced spinal cord injury. Journal of Neuroinflammation, 9, 100.
83. Mosharov, E. V., et al. (2009). Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron, 62(2), 218-229.
84. Munji, R. N., et al. (2011). Wnt signaling regulates neuronal differentiation of cortical intermediate progenitors. Journal of Neuroscience, 31(5), 1676-1687.
85. Murata, H., et al. (2011). A new cytosolic pathway from a Parkinson disease-associated kinase, BRPK/PINK1. Activation of Akt via mTORC2. Journal of Biological Chemistry, 286(9), 7182-7189.
86. Mythri, R. B., et al. (2011). Evaluation of markers of oxidative stress, antioxidant function and astrocytic proliferation in the striatum and frontal cortex of Parkinson's disease brains. Neurochemical Research, 36(8), 1452-1463.
87. Mytilineou, C., Kramer, B. C., & Yabut, J. A. (2002). Glutathione depletion and oxidative stress. Parkinsonism & Related Disorders, 8(6), 385-387.
88. Naguib, Y. M. (2000). Antioxidant activities of astaxanthin and related carotenoids. Journal of Agriculture and Food Chemistry, 48(4), 1150-1154.
89. 2+-mediated nitrosative stress in neurodegenerative diseases: Possible pharmacological strategies. Cell Calcium, 47(2), 190-197.
90. Nakamura, T., & Lipton, S. A. (2011). Redox modulation by S-nitrosylation contributes to protein misfolding, mitochondrial dynamics, and neuronal synaptic damage in neurodegenerative diseases. Cell Death and Differentiation, 18(9), 1478-1486.
91. Narendra, D. P., et al. (2010). PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biology, 8(1), e1000298.
92. Nicholls, D. G. (2010). Mitochondrial ion circuits. Essays in Biochemistry, 47, 25-35.
93. Novak, I. (2012). Mitophagy: A complex mechanism of mitochondrial removal. Antioxidants & Redox Signaling, 17(5), 794-802.
94. Okatsu, K., et al. (2012). PINK1 autophosphorylation upon membrane potential dissipation is essential for Parkin recruitment to damaged mitochondria. Nature Communications, 3, 1016.
95. Olanow, C. W., & McNaught, K. S. (2006). Ubiquitin-proteasome system and Parkinson's disease. Movement Disorders, 21(11), 1806-1823.
96. Pearce, R. K., et al. (1997). Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. Journal of Neural Transmission, 104(6-7), 661-677.
97. Plun-Favreau, H., et al. (2007). The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1. Nature Cell Biology, 9(11), 1243-1252.
98. Plun-Favreau, H., et al. (2008). What have PINK1 and HtrA2 genes told us about the role of mitochondria in Parkinson's disease? Annals of the New York Academy of Sciences, 1147, 30-36.
99. Prakash, N., et al. (2006). A Wnt1-regulated genetic network controls the identity and fate of midbrain-dopaminergic progenitors in vivo. Development, 133(1), 89-98.
100. Pridgeon, J. W., et al. (2007). PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biology, 5(7), e172.
101. Puopolo, M., Raviola, E., & Bean, B. P. (2007). Roles of subthreshold calcium current and sodium current in spontaneous firing of mouse midbrain dopamine neurons. Journal of Neuroscience, 27(3), 645-656.
102. Pyo, H., et al. (1998). Mitogen-activated protein kinases activated by lipopolysaccharide and beta-amyloid in cultured rat microglia. NeuroReport, 9(5), 871-874.
103. Qi, X., & Mochly-Rosen, D. (2008). The PKCdelta-Abl complex communicates ER stress to the mitochondria - an essential step in subsequent apoptosis. Journal of Cell Science, 121(6), 804-813.
104. Reichmann, H. (2011). View point: Etiology in Parkinson's disease. Dual hit or spreading intoxication. Journal of the Neurological Sciences, 310(1-2), 9-11.
105. Roberts, R. A., et al. (2010). Toxicological and pathophysiological roles of reactive oxygen and nitrogen species. Toxicology, 276(2), 85-94.
106. Rochet, J. C., Hay, B. A., & Guo, M. (2012). Molecular insights into Parkinson's disease. Progress in Molecular Biology and Translational Science, 107, 125-188.
107. Ryu, J., et al. (2000). Thrombin induces NO release from cultured rat microglia via protein kinase C, mitogen-activated protein kinase, and NF-kappa B. Journal of Biological Chemistry, 275(39), 29955-29959.
108. Selley, M. L. (1998). (E)-4-hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson's disease. Free Radical Biology & Medicine, 25(2), 169-174.
109. Sha, D., Chin, L. S., & Li, L. (2010). Phosphorylation of parkin by Parkinson disease-linked kinase PINK1 activates parkin E3 ligase function and NF-kB signaling. Human Molecular Genetics, 19(2), 352-363.
110. Shimura, H., et al. (2000). Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nature Genetics, 25(3), 302-305.
111. Shruster, A., et al. (2011). Wnt signaling pathway overcomes the disruption of neuronal differentiation of neural progenitor cells induced by oligomeric amyloid beta-peptide. Journal of Neurochemistry, 116(4), 522-529.
112. Shulman, J. M., De Jager, P. L., & Feany, M. B. (2011). Parkinson's disease: Genetics and pathogenesis. Annual Review of Pathology: Mechanisms of Disease, 6, 193-222.
113. Song, S., et al. (2013). Characterization of phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (PINK1) mutations associated with Parkinson's disease in mammalian cells and Drosophila. Journal of Biological Chemistry, 288(8), 5660-5672.
114. Sospedra, M., & Martin, R. (2005). Immunology of multiple sclerosis. Annual Review of Immunology, 23, 683-747.
115. Strickland, D., & Bertoni, J. M. (2004). Parkinson's prevalence estimated by a state registry. Movement Disorders, 19(3), 318-323.
116. Sun, X., et al. (2000). Interaction between protein kinase C delta and the c-Abl tyrosine kinase in the cellular response to oxidative stress. Journal of Biological Chemistry, 275(11), 7470-7473.
117. Sundal, C., et al. (2012). Autosomal dominant Parkinson's disease. Parkinsonism & Related Disorders, 18(Suppl 1), S7-S10.
118. Surmeier, D. J., et al. (2011). The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's disease. Neuroscience, 198, 221-231.
119. Tain, L. S., et al. (2009). Drosophila HtrA2 is dispensable for apoptosis but acts downstream of PINK1 independently from Parkin. Cell Death and Differentiation, 16(8), 1118-1125.
120. Toulouse, A., & Sullivan, A. M. (2008). Progress in Parkinson's disease-where do we stand? Progress in Neurobiology, 85(4), 376-392.
121. Valente, E. M., et al. (2004). Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science, 304(5674), 1158-1160.
122. Varcin, M., et al. (2012). Oxidative stress in genetic mouse models of Parkinson's disease. Oxidative Medicine and Cellular Longevity, 2012, 624925.
123. Vinish, M., Anand, A., & Prabhakar, S. (2011). Altered oxidative stress levels in Indian Parkinson's disease patients with PARK2 mutations. Acta Biochimica Polonica, 58(2), 165-169.
124. Wakabayashi, K., et al. (2007). The Lewy body in Parkinson's disease: Molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology, 27(5), 494-506.
125. Wexler, E. M., Geschwind, D. H., & Palmer, T. D. (2008). Lithium regulates adult hippocampal progenitor development through canonical Wnt pathway activation. Molecular Psychiatry, 13(3), 285-292.
126. Whitton, P. S. (2007). Inflammation as a causative factor in the aetiology of Parkinson's disease. British Journal of Pharmacology, 150(8), 963-976.
127. Whitworth, A. J., et al. (2008). Rhomboid-7 and HtrA2/Omi act in a common pathway with the Parkinson's disease factors Pink1 and Parkin. Disease Models & Mechanisms, 1(2-3), 168-174.
128. Wood-Kaczmar, A., et al. (2008). PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons. PLoS ONE, 3(6), e2455.
129. Yacoubian, T. A., & Standaert, D. G. (2009). Targets for neuroprotection in Parkinson's disease. Biochimica et Biophysica Acta, 1792(7), 676-687.
130. Yan, M. H., Wang, X., & Zhu, X. (2013). Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease. Free Radical Biology & Medicine, 62, 90-101.
131. Ye, Q., et al. (2013). Astaxanthin suppresses MPP+ -induced oxidative damage in PC12 cells through a Sp1/NR1 signaling pathway. Marine Drugs, 11(4), 1019-1034.
132. Yin, L., et al. (2010). Terminal differentiation of chronic myelogenous leukemia cells is induced by targeting of the MUC1-C oncoprotein. Cancer Biology & Therapy, 10(5), 483-491.
133. Yu, H., Pardoll, D., & Jove, R. (2009). STATs in cancer inflammation and immunity: A leading role for STAT3. Nature Reviews Cancer, 9(11), 798-809.
134. Yun, J., et al. (2008). Loss-of-function analysis suggests that Omi/HtrA2 is not an essential component of the PINK1/PARKIN pathway in vivo. Journal of Neuroscience, 28(53), 14500-14510.
135. Zecca, L., et al. (2004). The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proceedings of National Academic Science USA, 101(26), 9843-9848.
136. Zhang, L., et al. (2011). The Wnt/beta-catenin signaling pathway in the adult neurogenesis. European Journal of Neuroscience, 33(1), 1-8.
137. Zhang, W., et al. (2013). Human neuromelanin: An endogenous microglial activator for dopaminergic neuron death. Frontiers in Bioscience (Elite Edition), 5, 1-11.
138. Zhou, C., et al. (2008). The kinase domain of mitochondrial PINK1 faces the cytoplasm. Proceedings of National Academic Science USA, 105(33), 12022-12027.